2. Immunology/Inflammation Stem Cell/Wnt MAPK/ERK Pathway Membrane Transporter/Ion Channel
  3. FAP ERK GLUT
  4. BR103354

BR103354 is an orally active, selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and Glut1 that are reduced by co-treatment with hFGF21 and FAP, decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis.

For research use only. We do not sell to patients.

BR103354

BR103354 Chemical Structure

CAS No. : 2505339-87-5

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BR103354 Related Antibodies

Top Publications Citing Use of Products

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All GLUT Isoform Specific Products:

View All Isoforms
GLUT1 GLUT2 GLUT3 GLUT4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BR103354 is an orally active, selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and Glut1 that are reduced by co-treatment with hFGF21 and FAP, decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis[1].

IC50 & Target[1]

GLUT1

 

In Vitro

BR103354 (0.03 nM-100 μM; 60 min at 37°C) potently and selectively inhibits purified human FAP with an IC50 of 14 nM[1].
BR103354 inhibits serum FAP activity across mouse, cynomolgus monkey, and human samples with similar potency, with IC50 values ranging from 27 to 31 nM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BR103354 Related Antibodies

Western Blot Analysis[1]

Cell Line: Differentiated 3T3/L1 adipocytes
Concentration: 5 μM
Incubation Time: 2 h (pre-incubation of hFGF21 with FAP; then added to cells)
Result: Restored phosphorylated ERK and Glut1 levels that had been reduced by co-treatment of hFGF21 with FAP, matching levels observed with hFGF21 treatment alone.
Parmacokinetics
Species Dose Route Tmax Cmax T1/2 Bioavailability
Mice[1] 1 mg/kg p.o. 0.5 h 2.3 μg/mL 1.2 h 48.4 %
Mice[1] 5 mg/kg p.o. 0.5 h 7.2 μg/mL 1.1 h 48.4 %
Mice[1] 10 mg/kg p.o. 0.5 h 19.2 μg/mL 1.2 h 48.4 %
Mice[1] 100 mg/kg p.o. 1 h 66.0 μg/mL 4.0 h 48.4 %
Mice[1] 200 mg/kg p.o. 1 h 122.5 μg/mL 3.8 h 48.4 %
Rat[1] 10 mg/kg p.o. 1.1 h 4.4 μg/mL 3.5 h /
Monkey[1] 10 mg/kg i.n. 2.3 h 0.42 μg/mL 1.3 h /
Monkey[1] 30 mg/kg i.n. 2.3 h 2.0 μg/mL 2.8 h /
In Vivo

BR103354 (20-50 mg/kg; p.o.) reduces the non-fasting blood glucose AUC by 40%-45% in ob/ob mice, and inhibits FAP activity by more than 70% for up to 9 h[1].
BR103354 (20-50 mg/kg; p.o.; once daily; for 4 consecutive weeks) reduces non-fasting blood glucose levels in ob/ob mice, inhibits FAP activity by ≥80%, increases serum FGF21 levels by approximately 1.4-fold, and simultaneously improves their insulin resistance, glucose tolerance, and hepatic steatosis[1].
BR103354 (50 mg/kg; intranasal administration) inhibits FAP activity by 65%-83% and increases the level of intact FGF21 in normal cynomolgus monkeys by 1.5-3.5 folds[1].
BR103354 (10-30 mg/kg; p.o.; once daily; for 10 consecutive weeks) inhibits FAP activity, increases serum FGF21 levels by 1.5-1.9 folds, reduces levels of hepatic enzymes and metabolic biomarkers, and ameliorates hepatic steatosis and fibrosis in CDAHFD-induced NASH mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: ob/ob (8-week-old male; spontaneous obese, diabetic model)[1]
Dosage: 20 mg/kg; 50 mg/kg
Administration: p.o.; single dose
Result: Reduced average nonfasting blood glucose to 178 mg/dL (20 mg/kg group) and 154 mg/dL (50 mg/kg group) at 3 hours post-administration.
Decreased blood glucose AUC by 40-45% relative to control.
Inhibited FAP activity by more than 70% at 1 hour post-administration, with inhibition maintained up to 9 hours.
Elevated plasma intact hFGF21 levels until 3 hours post-administration, then dropped below 10 ng/mL by 6 hours.
Animal Model: ob/ob (8-week-old male; spontaneous obese, diabetic model)[1]
Dosage: 20 mg/kg; 50 mg/kg
Administration: p.o.; once daily; 4 weeks
Result: Significantly reduced nonfasting blood glucose levels starting at week 2 (P<0.01) and further reduced at week 3 (P<0.001) relative to vehicle.
Inhibited FAP activity by at least 80% at week 4 relative to vehicle.
Increased serum total FGF21 levels by approximately 1.4-fold at week 4.
Showed significantly improved glucose tolerance (reduced OGTT AUC) in the 50 mg/kg group.
Significantly reduced fasting body weight, liver weight, fasting blood glucose, insulin levels, and HOMA-IR relative to vehicle.
Significantly reduced serum ALT, AST, and total cholesterol levels; serum TG and NEFA levels were unaltered.
Decreased liver TG content, with reduced Oil Red O stained area relative to vehicle.
Reduced mRNA expression of lipogenesis/steatosis-related genes, and increased fatty acid oxidation-related genes (MCAD, PPARα) in liver.
Elevated white adipose tissue adiponectin mRNA expression.
Increased ERK phosphorylation in white adipose tissue relative to vehicle.
Animal Model: C57BL/6J (5-week-old male; NASH induced by CDAHFD feeding for 4 weeks prior to treatment)[1]
Dosage: 10 mg/kg; 30 mg/kg
Administration: p.o.; once daily; 10 weeks
Result: Inhibited FAP activity in a dose-dependent manner relative to vehicle.
Increased serum FGF21 levels by 1.5-1.9-fold in treatment groups.
Reduced plasma ALT, AST, total cholesterol, TG, and glucose levels relative to vehicle.
Significantly reduced steatosis scores and Picrosirius red staining (fibrosis) relative to vehicle.
Molecular Weight

415.42

Formula

C19H15F2N5O2S
CAS No.
SMILES

O=C(C1=CSC(CC2=CC=C(C=C2)C#N)=N1)NCC(N3[C@@H](CC(F)(C3)F)C#N)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BR103354 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BR1033542505339-87-5BR 103354BR-103354FAPERKGLUTFibroblast activation protein Extracellular signal regulated kinasesGlucose transporterprolyl oligopeptidasehuman FAPfibroblast activation proteinhERGdipeptidyl peptidase-related enzymesnon-alcoholic steatohepatitishuman fibroblast growth factor 21type 2 diabetesmouse FAPmonkey FAPInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BR103354
Cat. No.:
HY-182250
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.